Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Meda in-licenses Ceplene from EpiCept; later buys full rights; Immune Pharmaceuticals repurchases rights

Executive Summary

Meda AB (specialty pharmaceuticals) will exclusively sell cancer and pain drug developer EpiCept's acute myeloid leukemia therapy Ceplene (histamine dihydrochloride) in Europe, Japan, China, Australia, and other undisclosed Asian countries.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies